Safety and efficacy of nazartinib (EGF816) in adults with EGFR-mutant non-small-cell lung carcinoma: a multicentre, open-label, phase 1 study
Titel:
Safety and efficacy of nazartinib (EGF816) in adults with EGFR-mutant non-small-cell lung carcinoma: a multicentre, open-label, phase 1 study
Auteur:
Tan, Daniel S-W Leighl, Natasha B Riely, Gregory J Yang, James C-H Sequist, Lecia V Wolf, Juergen Seto, Takashi Felip, Enriqueta Aix, Santiago P Jonnaert, Maud Pan, Chun Tan, Eugene Y Ko, Jinnie Moody, Susan E Kim, Dong-Wan